Ingrezza (valbenazine) is approved for the treatment of tardive dyskinesia [1]. It is also indicated for chorea associated with Huntington's disease [1].
How does Ingrezza work for tardive dyskinesia?
Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor [1]. By inhibiting VMAT2, it reduces the reuptake of monoamines, such as dopamine, into presynaptic vesicles, which is believed to help alleviate the involuntary movements associated with tardive dyskinesia [1].
What are the other uses for Ingrezza?
Beyond tardive dyskinesia, Ingrezza is also approved to treat chorea, a symptom characterized by involuntary, irregular, and purposeless movements, that is associated with Huntington's disease [1].
When did Ingrezza receive its first FDA approval?
Ingrezza received its initial FDA approval for tardive dyskinesia in April 2017 [2]. Its approval for chorea associated with Huntington's disease came in August 2022 [2].
What is the typical dosage of Ingrezza?
The starting dose for Ingrezza in tardive dyskinesia is typically 40 mg once daily. The dose can be increased to 60 mg once daily based on tolerability and response [1]. For chorea associated with Huntington's disease, the recommended dose is also 40 mg to 60 mg once daily [1].
What are the common side effects of Ingrezza?
Common side effects of Ingrezza can include somnolence (sleepiness) and constipation [1]. Other potential side effects may occur, and patients should discuss any concerns with their healthcare provider [1].
Are there any major safety concerns with Ingrezza?
A key safety consideration for Ingrezza is the potential for somnolence, which can impair the ability to drive or operate machinery [1]. Patients should be advised to avoid these activities until they know how Ingrezza affects them [1].
What is the drug's patent status and when does exclusivity expire?
Information regarding the specific patent expiry dates for Ingrezza can be found on DrugPatentWatch.com. Generally, drug patents provide market exclusivity for a certain period, after which generic or biosimilar versions may become available. DrugPatentWatch.com tracks these patent and exclusivity details [3].
Who manufactures Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [1].